Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy

Oncogene

Volumn 30, Issue 15, 2011, Pages 1773-1783

  Li, L Y ^a,b   Dai, H Y ^a   Yeh, F L ^a   Kan, S F ^a   Lang, J ^c   Hsu, J L ^c   Jeng, L B ^a,d   Chen, Y H ^a   Sher, Y P ^a   Lin, W C ^a   Hung, M C ^a,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

fetoprotein; liver cancer; non viral gene therapy; VISA

Indexed keywords

ALPHA FETOPROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIKDD GENE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE VECTOR; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ALPHA-FETOPROTEINS; ANIMALS; ENHANCER ELEMENTS, GENETIC; GENE THERAPY; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PROMOTER REGIONS, GENETIC;

ANIMALIA; CYTOMEGALOVIRUS; MUS;

EID: 79954604414     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.558     Document Type: Article

References (29)

1. Abelev GI, Eraiser TL. (1999). Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol 9: 95-107. (Pubitemid 29265525)
2. Avila MA, Berasain C, Sangro B, Prieto J. (2006). New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884. (Pubitemid 43980482)
3. Bui LA, Butterfield LH, Kim JY, Ribas A, Seu P, Lau R et al. (1997). In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther 8: 2173-2182. (Pubitemid 28043555)
4. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM et al. (2004). Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 11: 740-747. (Pubitemid 39488472)
5. Chen SH, Hu CP, Chang CM. (1992). Hepatitis B virus replication in well differentiated mouse hepatocyte cell lines immortalized by plasmid DNA. Cancer Res 52: 1329-1335.
6. El-Serag HB, Rudolph KL. (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576. (Pubitemid 46890874)
7. Guan M, Rodriguez-Madoz JR, Alzuguren P, Gomar C, Kramer MG, Kochanek S et al. (2006). Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. Cancer Res 66: 1620-1629. (Pubitemid 43259946)
8. Hoofnagle JH. (2004). Hepatocellular carcinoma: summary and recommendations. Gastroenterology 127(Suppl 1): S319-S323. (Pubitemid 39423402)
9. Ido A, Uto H, Moriuchi A, Nagata K, Onaga Y, Onaga M et al. (2001). Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res 61: 3016-3021. (Pubitemid 32691948)
10. Izumi R, Shimizu K, Kiriyama M, Hashimoto T, Urade M, Yagi M et al. (1992). Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival. J Surg Oncol 49: 151-155.
11. Kim JW, Wang XW. (2003). Gene expression profiling of preneo-plastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 24: 363-369. (Pubitemid 36432629)
12. Lemken ML, Wybranietz WA, Schmidt U, Graepler F, Armeanu S, Bitzer M et al. (2005). Expression liver-directed genes by employing synthetic transcriptional control units. World J Gastroenterol 11: 5295-5302. (Pubitemid 41410295)
13. Llovet JM, Burroughs A, Bruix J. (2003). Hepatocellular carcinoma. Lancet 362: 1907-1917. (Pubitemid 37518510)
14. Lu SY, Sui YF, Li ZS, Pan CE, Ye J, Wang WY. (2003). Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma. World J Gastroenterol 9: 688-691. (Pubitemid 36531540)
15. Ma SH, Chen GG, Yip J, Lai PB. (2010). Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice. Gene Ther 17: 905-912.
16. Mawatari F, Tsuruta S, Ido A, Ueki T, Nakao K, Kato Y et al. (1998). Retrovirus-mediated gene therapy for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter. Cancer Gene Ther 5: 301-306. (Pubitemid 128640016)
17. Nakabayashi H, Hashimoto T, Miyao Y, Tjong KK, Chan J, Tamaoki T. (1991). A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Mol Cell Biol 11: 5885-5893. (Pubitemid 21895356)
18. Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. (Pubitemid 40372904)
19. Ren XW, Liang M, Meng X, Ye X, Ma H, Zhao Y et al. (2006). A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther 13: 159-168. (Pubitemid 43113417)
20. Schafer DF, Sorrell MF. (1999). Hepatocellular carcinoma. Lancet 353: 1253-1257. (Pubitemid 29168472)
21. Sher YP, Tzeng TF, Kan SF, Hsu J, Xie X, Han Z et al. (2009). Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. Oncogene 28: 3286-3295.
22. Shi YJ, Gong JP, Liu CA, Li XH, Mei Y, Mi C et al. (2004). Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP-producing hepatocar-cinoma cell. World J Gastroenterol 10: 186-189. (Pubitemid 38195258)
23. Stillwagon GB, Order SE, Guse C, Leibel SA, Asbell SO, Klein JL et al. (1991). Prognostic factors in unresectable hepato-cellular cancer: Radiation Therapy Oncology Group Study 83-01. Int J Radiat Oncol Biol Phys 20: 65-71.
24. Suriawinata A, Xu R. (2004). An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 24: 77-88. (Pubitemid 38496050)
25. Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S et al. (2002). E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhan-cer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 5: 627-634. (Pubitemid 34546093)
26. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. (1997). Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15: 647-652. (Pubitemid 27291165)
27. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT et al. (2009). A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther 8: 2375-2382.
28. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Ding Q et al. (2007). Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 12: 52-65. (Pubitemid 47001785)
29. Zufferey R, Donello JE, Trono D, Hope TJ. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886-2892. (Pubitemid 29135675)